Biogen Stock Upgraded to Overweight by Piper Sandler Following Apellis Buyout

Piper Sandler has raised Biogen's stock rating to Overweight, citing the company's acquisition of Apellis as the reason for the upgrade. This reflects a positive financial outlook for Biogen.